NCT01189760 - Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines | Biotech Hunter

Enrollment

917

Participants

Timeline

Start Date

September 1, 2010

Primary Completion Date

March 1, 2011

Study Completion Date

September 1, 2011

Conditions

Facial RhytidesCrow's Feet LinesGlabellar Lines

Interventions

BIOLOGICAL

onabotulinumtoxinA 24 U

24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.

BIOLOGICAL

onabotulinumtoxinA 44 U

44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart

DRUG

normal saline

Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.

Trial Locations (4)

Unknown

Newport Beach

Vancouver

Antibes

Berlin